| Detailed information |
|---|
| CancerLivER ID | 2132 |
| Biomarker | CYP3A4 |
| Biomarker Name/Symbol (given in Publication) | CYP3A4 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential biomarkers for the early stage of hepatitis B virus-associated hepatocarcinogenesis; not validated on large patient cohorts |
| Experimental Condition | HCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, |
| Level of significance | p < 0.05 |
| Source | Tissue and Cells |
| PMID | 23891548 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | HepG2, Hep3B and HEK293T cells were obtained from the American Type Culture Collection; 19 paired stage II and stage III HCC tumour tissues and their adjacent non-cancerous liver tissues |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2013 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02504099 |